title: [Synergistic Antitumor Effect of Amorphigenin Combined with Cisplatin in Human Lung Adenocarcinoma A549/DDP Cells].
abstract: BACKGROUND
  Amorphigenin, a rotenoid compouns, from seeds of Amorpha fruticosa, has been shown to possess anti-proliferation activities in several cancer cells. To explore the antitumor effects of amorphigenin on cisplatin-resistant human lung adenocarcinoma A549/DDP cells and explore the underlying mechanisms.
  
  
  METHODS
  CCK-8 assay was used to measure the proliferation of A549/DDP cells; Colony formation assay was used to measure the colony formation of A549/DDP cells; Flow cytometry assay was used to detect the apoptosis rates; Western blot analysis was used to explore the expression of apoptosis-related proteins (caspase-3 protein, PARP protein) and lung resistance protein (LRP).
  
  
  RESULTS
  Our results demonstrated that amorphigenin could inhibit the proliferation of A549/DDP cells with a inhibition concentration of 50% cell growth (IC50) at 48 h of (2.19±0.92) μmol/L. Amorphigenin could inhibit the colony formation ability and induce apoptosis of A549/DDP cells; Furthermore, amorphigenin combined with cisplatin showed synergistic proliferation-inhibitory effect and apoptosis-promoting effect in A549/DDP cells; reduced the expression of LRP of A549/DDP cells.
  
  
  CONCLUSIONS
  Amorphigenin remarkably inhibits the proliferation and induces apoptosis in A549/DDP cells. Combination of amorphigenin with cisplatin had the synergistic inhibitory effect on A549/DDP cells by downregulating the expression of LRP. .
authors.affiliation: Cancer Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China.
authors.forename: Hongzhen
authors.initials: H
authors.lastname: Zhong
authors.affiliation: Cancer Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China.
authors.forename: Yufang
authors.initials: Y
authors.lastname: Zuo
authors.affiliation: Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong Medical University, Zhanjiang 524000, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Wu
authors.affiliation: Cancer Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Peng
authors.affiliation: Cancer Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China.
authors.forename: Huiping
authors.initials: H
authors.lastname: He
authors.affiliation: Cancer Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Yang
authors.affiliation: Cancer Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China.
authors.forename: Chengnong
authors.initials: C
authors.lastname: Guan
authors.affiliation: Cancer Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China.
authors.forename: Zumin
authors.initials: Z
authors.lastname: Xu
mesh_terms: D000072283:A549 Cells; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D000077192:Adenocarcinoma of Lung; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000235:genetics / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D004357:Drug Synergism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D010936:Plant Extracts / Q000494:pharmacology*; D011065:Poly(ADP-ribose) Polymerases / Q000235:genetics / Q000378:metabolism; D012402:Rotenone / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D010936:Plant Extracts; D012402:Rotenone; C049148:amorphigenin; D011065:Poly(ADP-ribose) Polymerases; D053148:Caspase 3; D002945:Cisplatin